These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

700 related items for PubMed ID: 21163071

  • 21. [Short-term effects of chemotherapy combined with hydroxycamptothecine and oxaliplatin in treatment of recurrent and metastatic colorectal cancer].
    Yao Y, Sun YJ, Zhao H, Guo YW, Lin F, Cai X, Tang XC.
    Ai Zheng; 2006 Aug; 25(8):1035-8. PubMed ID: 16965689
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Oxaliplatin, irinotecan and cetuximab in advanced gastric cancer. A multicenter phase II trial (Gastric-2) of the Arbeitsgemeinschaft Medikamentose Tumortherapie (AGMT).
    Wöll E, Greil R, Eisterer W, Bechter O, Fridrik MA, Grünberger B, Zabernigg A, Mayrbäurl B, Russ G, Dlaska M, Obrist P, Thaler J.
    Anticancer Res; 2011 Dec; 31(12):4439-43. PubMed ID: 22199312
    [Abstract] [Full Text] [Related]

  • 24. Efficacy and safety of cetuximab/irinotecan in chemotherapy-refractory metastatic colorectal adenocarcinomas: a clinical practice setting, multicenter experience.
    Gebbia V, Del Prete S, Borsellino N, Ferraù F, Tralongo P, Verderame F, Leonardi V, Capasso E, Maiello E, Bordonaro R, Stinco S, Agostara B, Barone C.
    Clin Colorectal Cancer; 2006 Mar; 5(6):422-8. PubMed ID: 16635281
    [Abstract] [Full Text] [Related]

  • 25. Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis.
    Ji JH, Park SH, Lee J, Kim TW, Hong YS, Kim KP, Kim SY, Baek JY, Kang HJ, Shin SJ, Shim BY, Park YS.
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):223-30. PubMed ID: 23689915
    [Abstract] [Full Text] [Related]

  • 26. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
    Asseburg C, Frank M, Köhne CH, Hartmann JT, Griebsch I, Mohr A, Osowski U, Schulten J, Mittendorf T.
    Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994
    [Abstract] [Full Text] [Related]

  • 27. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
    Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E.
    N Engl J Med; 2004 Jul 22; 351(4):337-45. PubMed ID: 15269313
    [Abstract] [Full Text] [Related]

  • 28. [Short-term outcomes of 16 patients with non-small cell lung cancer receiving cetuximab combined with standard chemotherapy in the first and non-first line settings].
    Qiu HJ, Xia LP, Wang F, Guo GF, Zhou FF, Zhang B, Zhang L.
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Nov 22; 30(11):2423-6. PubMed ID: 21097395
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. A retrospective study of S-1 and oxaliplatin combination chemotherapy in patients with refractory pancreatic cancer.
    Takahara N, Isayama H, Nakai Y, Sasaki T, Hamada T, Uchino R, Mizuno S, Miyabayashi K, Kogure H, Yamamoto N, Sasahira N, Hirano K, Ijichi H, Tateishi K, Tada M, Koike K.
    Cancer Chemother Pharmacol; 2013 Nov 22; 72(5):985-90. PubMed ID: 23995699
    [Abstract] [Full Text] [Related]

  • 31. Putative contribution of CD56 positive cells in cetuximab treatment efficacy in first-line metastatic colorectal cancer patients.
    Maréchal R, De Schutter J, Nagy N, Demetter P, Lemmers A, Devière J, Salmon I, Tejpar S, Van Laethem JL.
    BMC Cancer; 2010 Jun 30; 10():340. PubMed ID: 20591136
    [Abstract] [Full Text] [Related]

  • 32. Predictive factors for the efficacy of cetuximab plus chemotherapy as salvage therapy in metastatic gastric cancer patients.
    Park SR, Kook MC, Choi IJ, Kim CG, Lee JY, Cho SJ, Kim YW, Ryu KW, Lee JH, Lee JS, Park YI, Kim NK.
    Cancer Chemother Pharmacol; 2010 Feb 30; 65(3):579-87. PubMed ID: 19629485
    [Abstract] [Full Text] [Related]

  • 33. [A retrospective study of irinotecan plus fluorouracil and l-leucovorin chemotherapy for advanced and metastatic colorectal cancer].
    Kamoshita N, Makita F, Kobayashi M, Matsuzaki Y, Kabeya K.
    Gan To Kagaku Ryoho; 2007 Mar 30; 34(3):397-401. PubMed ID: 17353631
    [Abstract] [Full Text] [Related]

  • 34. [Clinical observation of XELOX (Capecitabine puls Oxaliplatin): an adjuvant chemotherapy regimen used in stage III colorectal cancer].
    Diao C, Cheng RC, Zhang JM, Wei XP, Su YJ, Liu QY, Xu JB.
    Zhonghua Zhong Liu Za Zhi; 2008 Feb 30; 30(2):147-50. PubMed ID: 18646702
    [Abstract] [Full Text] [Related]

  • 35. The role of KRAS mutations in predicting the efficacy of cetuximab-plus-irinotecan therapy in irinotecan-refractory Korean metastatic colorectal cancer patients.
    Sohn BS, Kim TW, Lee JL, Ryu MH, Chang HM, Kang YK, Park HS, Na YS, Jang SJ, Kim JC, Lee JS.
    Oncology; 2009 Feb 30; 77(3-4):224-30. PubMed ID: 19738388
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer.
    Degirmenci M, Karaca B, Gorumlu G, Durusoy R, Demir Piskin G, Bozkurt MT, Cirak Y, Tunali D, Karabulut B, Sanli UA, Uslu R.
    Med Oncol; 2010 Sep 30; 27(3):585-91. PubMed ID: 19526201
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 35.